Skip to content
AnalystLens
Back to BBIOBalance Sheet

BridgeBio Pharma Long-Term Debt 2018-2026 | BBIO

Annual FY2018–FY2025 · quarterly through Q3 FY2026

Latest annual · FY2025

$2.01B

+359.0%YoY vs FY2024Source: 10-KFY2025

From $54.5M in FY2018 to $2.01B in FY2025: 36.8× in 7 years.

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY26$2.7B$2.7B$2.6B+31.0%Not reported
FY25$0−100.0%$0−100.0%$2.0B+360.2%$2.0B+359.0%
FY24$435M−0.2%$435M−1.1%$436M−1.2%$437M−2.0%
FY23$436M+0.4%$440M$442M$446M+3.6%
FY22$434M+378.3%Not reportedNot reported$431M+0.1%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date.

Key Statistics

Trend DirectionStable
CAGR

+85.1%

FY2020
$92.4M
FY2025
$2.01B

5 years selected · on the chart

Long-Term Debt History

Year-over-year comparison from 10-K annual reports

  1. $2.01B
YoY changeLargest recent move+366.1%in FY21Latest +359.0%

2 older moves run past ±150% (largest +366.1%); point at, tap or drag across the bars to read one.

Long-Term Debt, period by period

PeriodValueChangeSource
FY2025$2.01B+359.0%10-K
FY2024$437.3M−2.0%10-K
FY2023$446.4M+3.6%10-K
FY2022$431.0M+0.1%10-K
FY2021$430.8M+366.1%10-K
FY2020$92.4M+0.7%10-K
FY2019$91.8M+68.4%10-K
FY2018$54.5M—10-K

What is long-term debt?

Long-term debt includes bonds, mortgages, and other borrowings with maturities greater than one year.

What is BridgeBio Pharma's current long-term debt?

BridgeBio Pharma (BBIO) annual long-term debt for 2025 was $2.01B, a 358.99% increase from 2024. BridgeBio Pharma long-term debt for the quarter ending September 30, 2026 was $2.63B.

What was BridgeBio Pharma's long-term debt in 2024?

BridgeBio Pharma annual long-term debt for 2024 was $437.3M, a 2.04% decline from 2023.

What was BridgeBio Pharma's long-term debt in 2023?

BridgeBio Pharma annual long-term debt for 2023 was $446.4M, a 3.59% increase from 2022.

What is BridgeBio Pharma's 5-year long-term debt CAGR?

BridgeBio Pharma long-term debt grew at a compound annual growth rate (CAGR) of 85.08% from FY2020 to FY2025, going from $92.4M to $2.01B over 5 years.

Company
BridgeBio Pharma
Ticker
BBIO
Sector
Healthcare
Industry
Pharmaceutical Preparations